O-RADS US v2022: Assessment Categories and Risk Stratification of Adnexal Lesions — МЕДТРЕЙН Asia
General ultrasound diagnostics

O-RADS US v2022: Assessment Categories and Risk Stratification of Adnexal Lesions

Briefly. O-RADS US v2022 (ACR) is a consensus-based risk stratification system for adnexal lesions incorporating standardized ultrasound lexicon and the IOTA model. Categories ranging from 0 (incomplete evaluation) to 5 distribute lesions by malignancy probability and define management strategy accounting for menopausal status. Classic benign findings are classified by recognizable patterns.

O-RADS US (Ovarian-Adnexal Reporting and Data System) is a consensus-based risk assessment system for adnexal ovarian lesions developed by the ACR committee. The current version is O-RADS US v2022 (release date: November 2022). The system relies on standardized ultrasound lexicon of descriptors and integration of the IOTA model, with management strategy differentiated by premenopausal and postmenopausal patient status.

O-RADS US v2022 Assessment Categories

CategoryDescriptionManagement
O-RADS 0Incomplete evaluation — lesion features cannot be accurately characterized due to technical factorsRepeat ultrasound or MRI
O-RADS 1Normal ovary — no adnexal lesion presentNone [N/A]
O-RADS 2Almost certainly benign (physiologic cysts, simple cysts, etc.)By subtype and size

Classification Examples per v2022

According to the published O-RADS US v2022 table:

  • Physiologic cyst: follicle (≤3 cm) or corpus luteum (typically <3 cm) — category 1, no follow-up required.
  • Simple cyst >3 cm to 5 cm: management — no follow-up (None).
  • Simple cyst >5 cm but <10 cm: follow-up ultrasound at 12 months.
  • Solid lesion with acoustic shadowing, smooth margins, any size, color signal (CS) = 1: classified as classic benign pattern.

Categories 2 and above utilize lexicon descriptors and the IOTA model for risk assessment. Higher categories (up to 5) correspond to increasing malignancy probability; specific thresholds and management for categories 3–5 are not detailed in the provided excerpts [clarification needed].

Practical Principles of Application

For correct system application, it is important to apply appropriate lexicon terminology to classic benign lesions — this prevents false category elevation. Ambiguous descriptive terms such as "complex" or "heterogeneous" lesion should be avoided.

Frequently asked questions

What is the current version of O-RADS US?

O-RADS US v2022, release date November 2022 (ACR). It includes assessment categories and a list of classic benign lesions.

What does O-RADS 0 mean?

Incomplete evaluation: lesion features cannot be accurately characterized due to technical factors. Repeat ultrasound or MRI is recommended.

How is a simple cyst >5 cm but <10 cm classified?

According to v2022 table, such a simple cyst is recommended for follow-up ultrasound at 12 months.

Does the system account for menopausal status?

Yes, management strategy in O-RADS US v2022 is differentiated for premenopausal and postmenopausal patients and integrates the IOTA model.

How can category overestimation be avoided?

Apply appropriate lexicon terminology to classic benign findings and avoid ambiguous descriptors such as "complex" or "heterogeneous".

The material is intended for specialists and does not replace clinical judgment. Threshold values are periodically reviewed — refer to the current edition of the applicable consensus.
Sources: O-RADS™ US v2022 – Assessment Categories and Classic Benign Lesions (ACR, 2022); Andreotti RF et al. O-RADS US Risk Stratification and Management System: A Consensus Guideline from the ACR Ovarian-Adnexal Reporting and Data System Committee. Radiology 2020;294:168-85; Diagnostic Ultrasound: Abdomen & Pelvis, 2nd ed. (Kamaya et al., 2022); ACR-ACOG-AIUM-SPR-SRU Practice Parameter for the Performance of Ultrasound of the Female Pelvis (2024).
View specialty courses: General Ultrasound →
Спросить Alex Отвечу на любой вопрос · 24/7 · на любом языке